Applying Dry Powder Coatings - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Applying Dry Powder Coatings
The authors experiment with a resonant acoustic mixer as a method for dry powder coating.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 94-102

Results


Figure 2: Scanning electron microscope micrographs of unprocessed (top row), resonant acoustic mixer (RAM) processed without silicon dioxide (middle row), and RAM processed with aerosil R972 (bottom row) for ibuprofen (left column) and acetaminophen (right column). The RAM processed ibuprofen without silicon dioxide shows some surface abrasion or melting, and the RAM processed acetaminophen did not appear to change. (ALL IMAGES AND FIGURES ARE COURTESY OF THE AUTHORS, EXCEPT WHERE OTHERWISE NOTED)
Effect of RAM mixing on powder and particle properties. An examination of the ibuprofen and acetaminophen host particles after mixing showed slight changes to the surfaces of some of the host particles when processed in the RAM without silicon dioxide. Figure 2 shows what appears to be surface melting of an ibuprofen particle after mixing without silicon dioxide. Considering the relatively low melting point of ibuprofen (~70 C), this suggests that interparticle friction may have increased the temperature of the powder during processing significantly above ambient laboratory temperature (20–25 C). Some particle–particle abrasion may also have occurred during mixing in the absence of a glidant. However, the melting and abrasion did not appear in samples that were mixed with silicon dioxide, presumably because the glidant acted to significantly reduce the friction during mixing. No appreciable changes in particle size, morphology, or surface texture were observed for the acetaminophen particles. Further investigation is recommended to determine whether any significant heat was generated during the process, which may cause physical changes to sensitive host particles.


Table I: Particle-size distribution statistics for nprocessed and resonant acoustic mixer dry-powder-coated ibuprofen and acetaminophen.
The particle-size distributions of the unprocessed ibuprofen and acetaminophen host particles were compared with the silicon dioxide mixed powders after 10 minutes of processing to determine whether appreciable host particle attrition or agglomeration had occurred (see Table I). The apparent particle size of the two ibuprofen powders slightly increased after mixing with silicon dioxide. There was no appreciable change in the particle size of the acetaminophen after mixing with silicon dioxide. It is hypothesized that the smallest ibuprofen particles adhered to larger particles after mixing. Based on these results, the RAM did not appear to cause host particle attrition during dry powder coating, but for certain powders, the process could promote agglomeration or further ordered mixing.


Figure 3: Effect of resonant acoustic mixer mixing time on bulk density of host powders coated with 1% aerosil R972.
The influence of RAM mixing duration was assessed using host particles mixed with 1 wt% Aerosil R972 by periodic sampling. The extent of mixing was determined indirectly from bulk-density measurements because the silicon dioxide acts as a glidant to enable host-particle rearrangement when well dispersed over the host particles. In nearly all cases, the powders achieved a steady-state bulk density after approximately five minutes of mixing (see Figure 3), and therefore a five-minute mixing time was used in subsequent host-guest particle screening experiments as the standard mixing condition. It is currently hypothesized that mixing time at resonance can be used to scale up this process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here